JP2005525392A - 減少された鎮静及び失調効果を有する抗不安薬剤 - Google Patents

減少された鎮静及び失調効果を有する抗不安薬剤 Download PDF

Info

Publication number
JP2005525392A
JP2005525392A JP2003580300A JP2003580300A JP2005525392A JP 2005525392 A JP2005525392 A JP 2005525392A JP 2003580300 A JP2003580300 A JP 2003580300A JP 2003580300 A JP2003580300 A JP 2003580300A JP 2005525392 A JP2005525392 A JP 2005525392A
Authority
JP
Japan
Prior art keywords
cyclopropyl
thienyl
ring
substituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003580300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525392A5 (enExample
Inventor
エム. クック,ジェイムス
ファン,チ
ヒ,シアオフイ
リ,シオアヤン
ユ,ジアンミン
ハン,ドンメイ
レラス,スンジェザナ
エフ. マクエルロイ,ジョン
Original Assignee
ウィシス テクノロジー ファウンデーション,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィシス テクノロジー ファウンデーション,インコーポレイティド filed Critical ウィシス テクノロジー ファウンデーション,インコーポレイティド
Publication of JP2005525392A publication Critical patent/JP2005525392A/ja
Publication of JP2005525392A5 publication Critical patent/JP2005525392A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2003580300A 2002-03-28 2003-03-28 減少された鎮静及び失調効果を有する抗不安薬剤 Pending JP2005525392A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36840802P 2002-03-28 2002-03-28
PCT/US2003/009587 WO2003082832A2 (en) 2002-03-28 2003-03-28 Anxiolytic agents with reduced sedative and ataxic effects

Publications (2)

Publication Number Publication Date
JP2005525392A true JP2005525392A (ja) 2005-08-25
JP2005525392A5 JP2005525392A5 (enExample) 2008-01-24

Family

ID=28675480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003580300A Pending JP2005525392A (ja) 2002-03-28 2003-03-28 減少された鎮静及び失調効果を有する抗不安薬剤

Country Status (16)

Country Link
US (6) US7119196B2 (enExample)
EP (1) EP1490344B1 (enExample)
JP (1) JP2005525392A (enExample)
KR (2) KR100865410B1 (enExample)
CN (1) CN1642924A (enExample)
AT (1) ATE389640T1 (enExample)
AU (1) AU2003230754B2 (enExample)
BR (1) BR0308918A (enExample)
CA (1) CA2480869A1 (enExample)
DE (1) DE60319812T2 (enExample)
DK (1) DK1490344T3 (enExample)
ES (1) ES2300576T3 (enExample)
IL (1) IL163958A0 (enExample)
MX (1) MXPA04009332A (enExample)
NZ (1) NZ535517A (enExample)
WO (1) WO2003082832A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532989A (ja) * 2016-11-01 2019-11-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cns関連疾患を処置するための1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−チオン
JP2024535343A (ja) * 2021-09-24 2024-09-30 エフ. ホフマン-ラ ロシュ アーゲー GABAAγ1 PAMとしてのピリドジアゼピン誘導体

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47475E1 (en) * 2002-03-28 2019-07-02 Wisys Technology Foundation, Inc. Selective agents for pain suppression
AU2005260650A1 (en) 2004-06-30 2006-01-12 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US8119629B2 (en) * 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
US20100261711A1 (en) * 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
JP2013209292A (ja) * 2010-07-23 2013-10-10 Nippon Chemiphar Co Ltd P2x4受容体拮抗剤
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2885148A1 (en) 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
FR3010785B1 (fr) * 2013-09-18 2015-08-21 Snecma Procede de controle de la densite d'energie d'un faisceau laser par analyse d'image et dispositif correspondant
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido
EP4129297A1 (en) 2016-03-18 2023-02-08 UWM Research Foundation, Inc. Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists
AU2017313753B2 (en) 2016-08-16 2022-01-27 The Trustees Of Columbia University In The City Of New York GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
CN107056760A (zh) * 2017-01-22 2017-08-18 苏州楚凯药业有限公司 5,7位取代的1H‑苯并[e][1,4]二氮杂‑2(3H)‑酮衍生物的制备方法
CN107325101B (zh) * 2017-06-29 2019-03-26 上海合全药物研发有限公司 6-羟甲基-6,7-二氢-5h,9h-咪唑并二氮杂卓-8-羧酸叔丁酯的合成方法
CN107216332B (zh) * 2017-06-29 2019-04-30 上海药明康德新药开发有限公司 叔丁基-7-羟甲基-7,8-二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法
WO2019070910A1 (en) 2017-10-03 2019-04-11 Uwm Research Foundation, Inc. NEW POLYTHERAPY FOR ANXIETY, EPILEPSY AND PAIN DISORDERS
TWI878507B (zh) 2020-03-31 2025-04-01 瑞士商赫孚孟拉羅股份公司 作為 GABA A γ1 PAM 的新穎苯并二氮呯衍生物
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2024537773A (ja) 2021-09-29 2024-10-16 エフ. ホフマン-ラ ロシュ アーゲー GABA Aγ1 PAMとしての新規ベンゾジアゼピン誘導体
WO2023057415A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as positive allosteric modulators of the gaba a gamma1 receptor
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
WO2024030535A2 (en) * 2022-08-03 2024-02-08 The Johns Hopkins University Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2893992A (en) * 1959-07-07 I ii i i
US3886141A (en) * 1971-10-07 1975-05-27 Hoffmann La Roche Preparation of 5-pyridyl benzodiazepine utilizing hexamethylenetetramine
US4280957A (en) 1974-09-11 1981-07-28 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4440685A (en) * 1974-09-11 1984-04-03 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4401597A (en) 1978-05-15 1983-08-30 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
DE3435973A1 (de) * 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
ES2037013T3 (es) * 1986-01-21 1993-06-16 Boehringer Ingelheim Kg Procedimiento para preparar tieno-1,4-diazepinas.
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
MC1999A1 (fr) 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US5968176A (en) * 1997-05-29 1999-10-19 3Com Corporation Multilayer firewall system
EP1379511B1 (en) * 2001-04-12 2005-07-20 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
US7161904B2 (en) * 2002-06-04 2007-01-09 Fortinet, Inc. System and method for hierarchical metering in a virtual router based network switch
US7415723B2 (en) * 2002-06-11 2008-08-19 Pandya Ashish A Distributed network security system and a hardware processor therefor

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532989A (ja) * 2016-11-01 2019-11-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cns関連疾患を処置するための1,3−ジヒドロ−1,4−ベンゾジアゼピン−2−チオン
JP7139323B2 (ja) 2016-11-01 2022-09-20 エフ.ホフマン-ラ ロシュ アーゲー Cns関連疾患を処置するための1,3-ジヒドロ-1,4-ベンゾジアゼピン-2-チオン
JP2024535343A (ja) * 2021-09-24 2024-09-30 エフ. ホフマン-ラ ロシュ アーゲー GABAAγ1 PAMとしてのピリドジアゼピン誘導体
JP7899312B2 (ja) 2021-09-24 2026-08-03 エフ. ホフマン-ラ ロシュ アーゲー GABAAγ1 PAMとしてのピリドジアゼピン誘導体

Also Published As

Publication number Publication date
US20070054881A1 (en) 2007-03-08
US7235656B2 (en) 2007-06-26
US20080108605A1 (en) 2008-05-08
WO2003082832A3 (en) 2004-04-08
WO2003082832A2 (en) 2003-10-09
CA2480869A1 (en) 2003-10-09
KR20040098029A (ko) 2004-11-18
CN1642924A (zh) 2005-07-20
US20070299058A1 (en) 2007-12-27
IL163958A0 (en) 2005-12-18
US7119196B2 (en) 2006-10-10
US20100130481A1 (en) 2010-05-27
DE60319812T2 (de) 2009-04-23
AU2003230754A1 (en) 2003-10-13
MXPA04009332A (es) 2005-12-12
ATE389640T1 (de) 2008-04-15
NZ535517A (en) 2007-02-23
DK1490344T3 (da) 2008-06-16
EP1490344A2 (en) 2004-12-29
US20040082573A1 (en) 2004-04-29
DE60319812D1 (de) 2008-04-30
ES2300576T3 (es) 2008-06-16
US20070049580A1 (en) 2007-03-01
AU2003230754B2 (en) 2007-10-25
KR100865410B1 (ko) 2008-10-24
KR20080060286A (ko) 2008-07-01
EP1490344B1 (en) 2008-03-19
BR0308918A (pt) 2005-01-04

Similar Documents

Publication Publication Date Title
KR100865410B1 (ko) 진정 및 운동실조 효과가 감소된 항불안제
CN102292341B (zh) 对apo a有活性的噻吩并三唑并二氮杂*衍生物
US20100261711A1 (en) Selective anticonvulsant agents and their uses
US20100004226A1 (en) Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
KR19990087585A (ko) 신경학적 활성제로서의 아졸로벤즈아제핀 유도체
Walser et al. Triazolobenzo-and triazolothienodiazepines as potent antagonists of platelet activating factor
DK157615B (da) Analogifremgangsmaade til fremstilling af terapeutisk aktive imidazo oe1,5-aaaoe1,4aa diazepin-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
CH631177A5 (de) Verfahren zur herstellung von diazepinderivaten.
EA003332B1 (ru) Замещенное производное триазолопиридазина, фармацевтические композиции, приготовленные на его основе
JP2023522099A (ja) Gaba aガンマ1 pamとしてのベンゾジアゼピン誘導体
AU2022351080A1 (en) Pyrido diazepine derivatives as gaba a gamma1 pam
JP2024534554A (ja) Gaba aガンマ1 pamとしてのベンゾジアゼピン誘導体
JP2024536394A (ja) Gaba aガンマ1受容体のポジティブアロステリックモジュレーターとしてのシクロヘプタ-チエノ-ジアゼピン誘導体
DK162495B (da) Analogifremgangsmaade til fremstilling af terapeutisk aktive imidazooe1,5-aaaoe1,4aadiazepin-forbindelser eller farmaceutisk acceptable salte deraf
EP1925614A1 (en) Anxiolytic agents with reduced sedative and ataxic effects
HK40104205A (en) Cyclohepta-thieno-diazepine derivatives as positive allosteric modulators of the gaba a gamma1 receptor
NZ547480A (en) Anxiolytic agents with reduced sedative and ataxic effects
AU2007221890A1 (en) Anxiolytic agents with reduced sedative and ataxic effects
HRP20000555A2 (en) SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PYRIDAZINE

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071128

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20071128

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20071221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080617